volume 29, issue 2, P197-205 2014
DOI: 10.3109/02688697.2014.994473
View full text
|
|
Share
Stavros Polyzoidis, Juel Tuazon, Lucy Brazil, Ronald Beaney, Safa Taha Al-Sarraj, Lawrence Doey, Jamie Logan, Victoria Hurwitz, Jozef Jarosz, Ranjeev Bhangoo, Richard Gullan, Aleksandar Mijovic, Mark Richardson, Farzin Farzaneh et al.

Abstract: Dendritic cell (DC) immunotherapy is developing as a promising treatment modality for patients with glioblastoma multiforme (GBM). The aim of this article is to review the data from clinical trials and prospective studies evaluating the safety and efficacy of DC vaccines for newly diagnosed (ND)- and recurrent (Rec)-GBM and for other high-grade gliomas (HGGs). By searching all major databases we identified and reviewed twenty-two (n=22) such studies, twenty (n=20) of which were phase I and II trials, one was a…

expand abstract